• About
  • Blog
  1. Home
  3. Blog
  5. Companies
  7. CNCE

Concert Pharmaceuticals, Inc.(CNCE)

NASDAQ Global Market
Sector: Healthcare | Industry: Biotechnology
Concert Pharmaceuticals, Inc. logo

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Latest News & Analysis

Sun Pharma's acquisition of Concert Pharmaceuticals and the potential of Deuruxolitinib for alopecia areata treatment. News and Market Analysis.
Feb 21, 2025

Sun Pharma's Acquisition of Concert Pharma: A Deep Dive

A deep dive into Concert Pharmaceuticals' acquisition by Sun Pharma, focusing on Deuruxolitinib, Alopecia Areata, and shareholder value.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.